ANZCTR search results

The primary objective of the trial is to determine, in patients who have undergone surgery with curative intent for high-risk CSCC of the head and neck, whether there is a difference in time to loco-regional relapse between patients treated with post-operative concurrent chemo-radiotherapy ,consisting of Carboplatin, and post-operative radiotherapy alone. The target sample size for the trial is 266 patients and will take 3-4 years to accrue, based on an anticipated accrual of 80 patients/year. A further 2 years follow up is required.

The researchers propose that it may be corpus invasion, rather than tumour volume per se, which is one of the important determinants of ultimate outcome in cervix cancer. The aim of the proposed prospective, multicentre study, is to confirm the results of our retrospective studies, specifically that corpus invasion or tumour volume or both contribute important prognostic information over and above that provided by the currently used International Federation of Gynecology and Obstetrics (FIGO) staging system. A successful outcome would have important implications for the staging, and management as well as the biologic understanding of the behaviour of cervical cancer.

The project is a simple randomised placebo controlled trial of probiotics for very premature infants to determine whether the probiotics reduce late onset infection and associated morbidity and mortality.

In this study the sponsor want to find out if zonisamide can be used on its own to control epilepsy. To find out if zonisamide works on its own, we are comparing it to another drug that we already know works: this drug is called carbamazepine (carb-a-maze-a-peen). We also want to get some more information on the safety of zonisamide.

The proposed study will examine if intranasal oxytocin can modulate the neural circuitry (especially the amygdala) response to threat in patients with Generalised Social Anxiety Disorder (GSAD). Two treatment conditions are involved: Oxytocin vs. Placebo. Participants (20 GSAD, 20 healthy controls) are required to undergo two functional magnetic resonsonance imaging (fMRI) sessions during which they will be asked to complete two emotional facial expression tasks. It is hypothesised that under placebo, patients with GSAD will show exaggerated amygdala activity as well as functional connectivity to threatening (i.e. angry and fearful) facial stimuli compared to healthy controls. Under oxytocin, such effects will be absent and amgydala activation and functional connectivity during threat processing will be reduced.

This is a pilot study to test in a small number of patients a holistic approach to acne treatment utilising a facial cleanser and topical gel treatment combined with an oral supplement combining natural ingredients which should not cause local irritation or lead to resistant organisms. The unique combination of natural ingredients aims to both cleanse the skin and target internal factors that will assist to promote healthy skin and to help alleviate acne. The Sponsor is looking to develop a suitable natural alternative to currently available pharmaceutical products for the treatment of mild to moderate acne.

Stimulant medication can be associated with slowing of growth in children with attention deficit hyperactivity disorder (ADHD), possibly by appetite suppression mediated by hormones such as leptin and ghrelin. Twelve healthy adult volunteers will have fasting blood tests for leptin, ghrelin, insulin and glucose, with these tests repeated after a meal. This will be done twice, once on medication (dexamphetamine or methylphenidate) and once on placebo. The effect of medication on food intake and alertness will be tested, together with subjects’ assessments of appetite and medication side effects.

The major concern for women on long term follow up after breast cancer has been treated, is fear of the reoccurrence of disease. This study will test a new strategy to prevent disease reocurrence and death due to breast cancer. The purpose of the study is to find out whether later re-treatment of participants with adjuvant letrozole therapy can prevent or delay new breast cancers from reoccurring in postmenopausal women previously treated with adjuvant endocrine therapy

Individuals with symptomatic CAD probably constitute a population at high risk for accelerated decline in cognitive function, because of the overlap between Alzheimer’s disease, vascular dementia and the risk factors for both. Appropriate clinical decision-making for these patients depends on the accurate understanding of the prevalence of prodromal conditions such as MCI, the incidence of PPCD and how they affect the rate of conversion to dementia in these patients.

This study compares metformin (current first-line medication) to rosiglitazone (a newer diabetic medication currently approved for combination use). Whilst there is good evidence for the benefits of rosiglitazone use in other populations, in light of the known weight gain effects of pioglitazone we believe further assessment is required in Indigenous Australians (in whom there is a strong predisposition for central fat deposition). This study will provide evidence regarding the medication appropirate for first line medication in Type 2 diabetes in this high risk population. This study will assist clinicians to make evidenced-based decisions regarding initial medical management of those with Type 2 diabetes (where there is currently a gap in evidence).